News | Radiation Therapy | October 07, 2016

Philips Unveils Advanced Radiation Oncology Imaging, Treatment Planning Innovations at ASTRO 2016

Company highlights latest version of CT Big Bore, Pinnacle3 treatment planning software and Ingenia MR-guided radiotherapy

Philips Healthcare, ASTRO 2016, radiation therapy, CT Big Bore, Ingenia MR-RT, Pinnacle treatment planning

October 7, 2016 — Philips Healthcare featured its latest integrated imaging and treatment planning solutions for radiation oncology at the American Society for Therapeutic Radiology and Oncology’s (ASTRO) 58th Annual Meeting, Sept. 25-28 in Boston. Designed to fit the unique needs of radiation oncology clinicians and patients, these solutions have been developed to put more control in the hands of the clinician, with the intent to improve workflow and operational efficiencies, drive procedure accuracy and ultimately improve care.

Over the past few years, cancer care has evolved to deliver more advanced treatments and technologies that do not always integrate seamlessly. For example, the treatment plan plays a big role in determining the quality of the treatment itself. For most patients, this means waiting for a week or more after their simulation scan to start their treatment, which can lead to increased anxiety. According to the National Cancer Institute, in many cases, this not only affects a patient’s ability to cope with treatment, but also impacts their quality of life. As technology and treatments for cancer advance, the patient experience remains first and foremost. 

The Philips booth at ASTRO 2016 showcased the company’s advanced solutions enhancing its integrated radiation oncology approach with a full suite to help clinicians deliver quality cancer care to improve both the patient and staff experience.

Meeting offerings included the following:

  • CT Big Bore v4.2 with Tumor LOC and iPatient Platform – A computed tomography (CT) simulation solution designed for every cancer patient, delivering accuracy, reliability and an efficient workflow to drive clinical confidence in cancer treatment. Now integrated with both Philips’ Tumor LOC technology and iPatient Platform, Big Bore offers more powerful simulation and advanced marking tools to help speed time to treatment.    Powered by Pinnacle3, TumorLOC integrates scanning and planning to simplify and accelerate patient marking and CT simulation at the scanner console. Philips’ iPatient platform provides consistent image quality from scan-to-scan through patient-centered workflows for both routine and advanced 4-D imaging applications, making patient setup fast and easy.
  • Ingenia MR-RT – a dedicated magnetic resonance (MR) simulation platform providing clinicians with high-quality MR images acquired in the treatment position to help visualize targets and critical structures, allowing them to design the best possible treatment plans. The MR-only simulation for prostate treatment planning was recently given 510(k) clearance by the U.S. Food and Drug Administration (FDA). At ASTRO, Philips also showcased developments in intelligent workflow automation, such as automated contouring on MR-only based datasets (a work in progress).
  • Pinnacle3  — Now with a new intuitive user interface, Pinnacle³ offers seamless integration that enhances planning efficiency and quality while making plan workflow faster and less iterative. Pinnacle3 intelligent automation simplifies and accelerates the intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) planning process. Smart automation tools enable the user to create plans with limited clinician intervention while reducing the dose variability of manual planning workflows.

For more information: www.usa.philips.com/healthcare

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing  synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of  the anatomy.

A set of synthetic CT images created from T1 and T2 weighted MR imaging of a prostate/rectum phantom at Henry Ford Hospital. The hospital is one of the research centers developing synthetic CT imaging for treatment planning to avoid the need for CT scans of a patient just for treatment planning purposes when they already have a more detailed soft tissue MRI exam of the anatomy.

Feature | Radiation Oncology | May 29, 2019 | By Jeff Zagoudis
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin